The DC Cohort Longitudinal HIV Status Neutral Study (NCT01206920) | Clinical Trial Compass
RecruitingNot Applicable
The DC Cohort Longitudinal HIV Status Neutral Study
United States19,000 participantsStarted 2011-01
Plain-language summary
The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes, and improve the quality of care for patients diagnosed with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) or at higher risk for acquiring HIV and receiving care in Washington, DC.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Treatment Cohort Inclusion Criteria:
* Patient is receiving care for HIV at one or more of the twelve participating clinics in the DC Cohort.
* Patient is either age 18 years or older, or seeks HIV care independently and is able to understand and sign informed consent.
* Patient is a minor who is consented by a parent or legal guardian.
Treatment Cohort Exclusion Criteria:
* Patient is unable or refuses to provide informed consent.
* Minor children ages 12 through 17 who are unaware of their HIV status
Prevention Cohort Inclusion Criteria:
Persons receiving any antiretroviral prescription without evidence of HIV or Hepatitis B infection
* PrEP (e.g., TDF/FTC, Descovy, Apretude)
* Combination ART indicative of nPEP in an HIV-uninfected person
* Persons receiving an antiretroviral prescription indicative of DoxyPEP Doxycycline 200mg PO taken within 72 hrs of unprotected sexual encounter (or variations thereof where clearly not prescribed as a treatment course)
* Test positive for ≥1 bacterial STI (positive gonorrhea (GC/NG) or chlamydia (CT) test or positive syphilis test requiring treatment within one year)
* 2 bacterial STI (GC, chlamydia, syphilis) tests at 2 or more different encounters
* 2 HIV tests at 2 or more different encounters
* Patient requesting PrEP at their clinical visit
* Patient requesting nPEP at their clinical visit
* People who identify as injecting drugs
Patients with a Z29.81 Encounter for HIV pre-exposure prophylaxis
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
viral suppression among persons with HIV
Timeframe: through study completion, an average of 10 years from enrollment to the end of study follow up
2
clinical outcomes persons at higher risk for acquiring HIV
Timeframe: through study completion, an average of 5 years from enrollment to the end of study follow up period